Bloomington, Indiana
Biologics development and manufacturing operation in Bloomington.
Company-issued releases from the past 90 days. Company claims have not been independently verified.
Catalent announced a $4.1 billion equivalent term loan and a $600 million revolving credit facility. The company expects about $100 million in annual interest savings. This is a corporate financing announcement, not a Bloomington-specific investment.
Read original release ↗In a corporate announcement, Catalent and Taysha said they expanded their partnership for investigational Rett syndrome therapy TSHA-102, subject to potential FDA approval. The planned manufacturing is in Harmans, Maryland; this release does not announce a Bloomington project.
Read original release ↗Catalent announced a corporate agreement to support late-stage development and potential commercial supply of Nanoscope’s investigational MCO-010 gene therapy. The company described packaging validation and distribution support; it did not announce a Bloomington project.
Read original release ↗